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One of the most challenging issues facing
providers treating patients with human immunode-
ficiency virus - 1 (HIV) infection is the complex
problem of drug interactions associated with high-
ly active antiretroviral therapy (HAART).
Guidelines for the initial treatment of HIV infection
recommend the use of at least three antiretroviral
medications, each of which is associated with sig-
nificant drug interactions.1 Further increasing the
risk of drug interactions is the concurrent treat-
ment of co-morbid disease states and therapies
for prevention and/or treatment of opportunistic
infections (OIs). This review focuses on the clini-
cally significant drug interaction associated with
the use of HAART.
Drug Interaction Overview
Currently, there are 21 medications from four dif-
ferent classes licensed in the United States for the
treatment of HIV infection.  Drug interactions
associated with HIV medications can be broadly
classified into those that alter pharmacokinetics
and those that alter pharmacodynamics.2
Pharmacokinetic drug interactions generally result
in a change in pharmacokinetic parameters, such
as the area under the curve (AUC), which is a
common measure of drug exposure, peak con-
centration (Cmax), trough concentration, or half-
life. Conversely, pharmacodynamic interactions
result in alterations in the pharmacologic activity of
the medication; generally not causing a change in
pharmacokinetic parameters. The vast majority of
drug interactions encountered in HIV medicine are
pharmacokinetic in nature and occur as a result of
a change in the absorption, distribution,
metabolism or elimination of either the HIV
medication itself or the concurrently administered
medication.3
The cytochrome P450 (CYP450) enzyme system
is responsible for the biotransformation of drugs
from active to inactive metabolites that are readily
excreted by the body. Given the effects of the pro-
tease inhibitor (PI) and non-nucleoside reverse
transcriptase (NNRTI) class on the CYP450 sys-
tem, metabolism drug interactions are most com-
mon and problematic when prescribing HAART.
Though numerous isoenzymes of CYP450 have
been identified, the enzymes responsible for the
elimination of the majority of drugs used in HAART
are CYP3A4, CYP1A2, and CYP2D6. Table 1
describes the route of elimination for HAART.
Nucleoside/nucleotide reverse
transcriptase inhibitors 
Drug interactions associated with the nucleoside
(NRTI) and nucleotide (NtRTI) classes are mini-
mal, as these medications are not metabolized by
the CYP450 system. However, drug interactions
may still occur within this class. 
The currently available NRTIs and NtRTI include
zidovudine, didanosine, zalcitabine, stavudine,
lamivudine, abacavir, emtricitabine, and tenofovir. 
Drug interactions with zidovudine are minimal;
however, one of the few pharmacodynamic inter-
actions encountered in HIV medicine occurs with
co-administered zidovudine and stavudine. Since
both of these NRTIs are thymidine analogues,
they can compete for the same phosphorylation
site in the growing chain of HIV DNA, resulting in
an antagonistic, pharmacodynamic interaction.3
These two agents should therefore never be com-
bined. 
The use of didanosine (ddI) is often complicated
by drug interactions. The buffered tablet formula-
tio , which contains magnesium and calcium to
improve systemic absorption, interacts with cer-
tain antibiotics.4 As a result of the buffer chelating
the antibiotic, reduced ciprofloxacin, tetracycline
or doxycycline absorption may occur. To minimize
this interaction, ddI should be administered at
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least two hours after or six hours before the
fluoroquinolone.5 Concurrent use of ddI-
buffered tablet may also impair the absorption
of the protease inhibitor (PI) atazanavir, since
atazanavir requires an acidic environment for
absorption.6 Patients should take a ddI-
buffered tablet two hours after or one hour
before taking atazanavir to minimize the inter-
action. Alternatively, use of the enteric-coated
capsule formulation is an option; however,
providers need to be sure that patients sepa-
rate ddI and atazanavir since their dietary
restrictions differ.6,7
Probably the most significant ddI drug inter-
action reported occurs when didanosine is
used concurrently with the NtRTI tenofovir.
When enteric-coated ddI is co-administered
with tenofovir, the ddI AUC increases by
60%.8 As a result, the recommendation for
patients weighing >60kg who receive these
medications concurrently is to reduce the ddI
dosage to 250mg once daily. For patients
weighing <60kg, no specific guidelines are
available for ddI dosing; however, reduction
to 200mg once daily is likely warranted. For
severely underweight patients, providers may
consider an even further ddI dosage reduc-
tion to 125mg once daily. Due to the magni-
tude of this interaction, all patients receiving
concurrent tenofovir and ddI should be moni-
tored closely for ddI-related toxicities such as
pancreatitis, hyperlactatemia, and lactic aci-
dosis, regardless of ddI dosage adjustments.  
Non Nucleoside Reverse
Transcriptase Inhibitors
Three NNRTIs are currently licensed for use
in the US: nevirapine, delavirdine, and
efavirenz. Drugs in this class are prone to
drug interactions, given the fact that they are
extensively metabolized via CYP3A4 and can
act as either inducers or inhibitors of
CYP3A4. Nevirapine and efavirenz are, in
general, inducers of CYP3A4, while delavir-
dine is an inhibitor of CYP3A4. When one of
these agents is combined with a medication
that is also metabolized by CYP3A4, a drug
interaction is likely to occur.  
Numerous drug interactions with nevirapine
have been identified. Nevirapine is a CYP3A4
inducer, therefore most drug interactions
associated with it lead to an increase in
metabolism and reduced concentration of the
co-administered drug. For example, when
nevirapine is given concurrently with
methadone, withdrawal symptoms may occur
as a result of reduced methadone levels.9-12
When using methadone and nevirapine con-
currently, patients should be monitored close-
ly for signs and symptoms of methadone
withdrawal. Since the full effects of CYP3A4
induction may take time, signs of withdrawal
may occur one to two weeks (or longer) after
nevirapine is added to methadone. An
increase in methadone dosage may be nec-
essary after the addition of nevirapine. 
Concurrent nevirapine and oral contraceptive
use may lead to contraceptive failure; there-
fore providers should recommend alternate
methods of birth control.13 Rifabutin and
rifampin are also potent CYP3A4 inducers
and have been shown to reduce nevirapine
trough concentrations by 16% and 37%,
respectively. Therefore, patients on nevirap-
ine who require anti-mycobacterial therapy
should be given rifabutin to minimize the
reduction in nevirapine drug levels.  
Efavirenz is a potent inducer of CYP3A4 in
vivo. As with nevirapine, CYP3A4 induction
properties of efavirenz can result in reduced
concentrations of concurrently administered
drugs that are also metabolized by CYP3A4.
In vitro data also suggest that efavirenz can
inhibit CYP3A4. Efavirenz is therefore con-
traindicated with midazolam, triazolam, and
ergotamine derivatives since there is a poten-
tial for increased drug concentrations of these
medications and associated toxicity.14
Despite the inclusion of these contraindicated
medications in the product labeling, no pub-
lished case reports to date have either proven
or refuted the validity of these interactions.
Concurrent use of the macrolide antibiotic
clarithromycin should be avoided in patients
receiving concurrent efavirenz.  When used
together, the clarithromycin AUC and Cmax
decreased by 39% and 26%, respectively.14
Therefore, clinicians may consider using
azithromycin instead, as CYP450 drug inter-
actions are unlikely with this medication. 
Similar to nevirapine, methadone withdrawal
has also been reported with concurrent use of
efavirenz and methadone. This is more likely
to occur when adding efavirenz to a stable
methadone regimen.12 Providers should be
aware that the full effect of methadone with-
drawal may take one to two weeks. Any
change to antiretroviral therapy (ART) regi-
mens should be communicated to methadone
maintenance providers so that potential drug
interactions may be anticipated and avoided. 
Concurrent use of efavirenz with rifampin has
been shown to reduce the AUC and Cmax of
favirenz by 26% and 20%, respectively.
Although the clinical significance of this inter-
action is unknown, providers should increase
the efavirenz dosage to 800mg daily to offset
this interaction when using rifampin to treat
2
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TABLE 1: Routes of Elimination of Antiretroviral Agents and the
Effect on CYP450
Drug
Zidovudine 
(AZT, ZDV)
Didanosine (ddI)
Zalcitabine (ddC)
Stavudine (d4T)
Lamivudine (3TC)
Tenofovir (TDF)
Abacavir (ABC)
Emtricitabine (FTC)
Nevirapine (NVP)
Delavirdine (DLV)
Efavirenz (EFV)
Saquinavir (SQV)
Ritonavir (RTV)
Indinavir (IDV)
Nelfinavir (NFV)
Amprenavir (APV)
Lopinavir/ritonavir
(LPV/rtv)
Ataznavir (ATZ)
Fosamprenavir (FPV)
Enfuvirtide (ENF)
Elimination
Hepatic metabolism with
renal excretion
Renal excretion 50%
Renal excretion 70%
Renal excretion 50%
Renal excretion 70%
Renal excretion 70-80%
Hepatic
Renal excretion 86%
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Hepatic
Effect on CYP450 System
None
None
None
None
None
None
Insignificant
None
CYP3A4 inducer
CYP3A4 inhibitor
CYP3A4 inducer/inhibitor
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP2D6 inhibitor
(3A4 inhibition >2D6)
3A4 and CYP1A2 inducer
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP3A4 inhibitor
CYP2D6 inhibitor
(3A4 inhibition >2D6)
3A4 and CYP1A2 inducer
CYP3A4 inhibitor, CYP1A2,
CYP2C9 inhibitor
CYP3A4 inhibitor
None
Adapted from Reference 21.
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Dear Colleagues: 
Currently, there are twenty-one medications that have been FDA approved for the treatm nt
of HIV infection. Most HIV-infected persons who have access to treatment are experiencing
highly active antiretroviral therapy- (HAART) associated immune reconstitution, are less
likely to develop an opportunistic infection or malignancy, and are living longer.
However, as we wade with our patients into this ever-growing pool of medications, the risks
associated with polypharmacy have increased exponentially.  Drug-drug interactions have
been recognized that can lead to life-threatening toxicities or subtherapeutic medication lev-
els. Clinicians who are not knowledgeable about these potential interactions can unwitting-
ly contribute to the development of resistant strains of HIV.  Alternatively, uninformed choic-
es can lead to the failure of opportunistic infection prophylaxis or treatment.    
The onus is therefore upon us as HIV care providers to be aware of the myriad of potential
adverse interactions that accompany the medications in our armamentarium. In addition, we
must be cognizant of interactions that may occur with over-the-counter drugs, herbal reme-
dies, and recreational drugs. This month's lead article by Dr. John Faragon of Albany
College of Pharmacy and Dr. Peter Piliero of Albany Medical College provides a thorough
review of the clinically significant drug interactions associated with HAART. This month's
HIV 101 addresses drug interactions that can occur with the concurrent use HAART and
methadone.
Next month we will bring you an update on Tuberculosis and a Spotlight on the growing role
of electronic medical records in the management of chronic diseases, with a focus on prod-
ucts that are currently being used in the correctional setting.
As always, we welcome your feedback and suggestions.  We value the collaborative rela-
tionship that we have developed with you, our readers and colleagues in correctional health
care.  It is our sincere hope that HEPP Report's first issue of 2004 meets your expectations,
and that we continue to serve as a useful resource to you throughout the coming year.    
Sincerely,
Joseph Bick, MD
Julia Noguchi, MA
Letter from the Editor
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4tuberculosis.15 Another alternative would be
to use rifabutin instead of rifampin; current
guidelines suggest that the rifabutin dose be
increased to 450 mg daily and the dosage of
efavirenz should remain at 600mg once daily. 
Unlike efavirenz and nevirapine, delavirdine is
a potent inhibitor of CYP3A4. As a result, con-
current administration of drugs metabolized
by the same isoenzyme are likely to cause
increased drug levels and potential drug toxi-
city. Drugs that are likely to have increased
serum levels when used concurrently with
delavirdine include alprazolam, midazolam,
triazolam, sildenafil, ergot alkaloid deriva-
tives, nifedipine, and the HMGCoA-reductase
inhibitors simvastatin and lovastatin.16
Concurrent use of these medications should
be avoided in patients receiving delavirdine. 
The medications rifampin and rifabutin have
also been shown to reduce the AUC of
delavirdine by 96% and 80%, respectively.
Current guidelines for ART recommend that
these medications be avoided in patients
receiving concurrent delavirdine due to the
high risk for development of resistance and
virologic failure.15,16
Other potential drug interactions with the
entire NNRTI class include the anticonvul-
sants phenytoin, carbamazepine, and pheno-
barbital. Since these medications induce the
CYP450 system, reduced drug levels of
delavirdine, efavirenz, and nevirapine may
occur and should be avoided if possible. A
potential alternative is the medication leve-
tiracetam and may be considered with con-
current ARV treatment, as it does not have
significant CYP450 interactions. When pre-
scribing levetiracetam, the patient should
have close follow-up with a neurologist. 
In treating patients who have failed their first
regimen, or are in deeper salvage therapy,
providers may be forced to use NNRTIs and
PIs together. Providers need to be cognizant
of dosage changes required when using
these two classes concurrently, given the
effect of both classes on the CYP3A4 system.
As the NNRTIs efavirenz and nevirapine are
known inducers of the CYP3A4 system, sig-
nificant reductions in PI levels may occur
when using these drugs concurrently. For
example, when using efavirenz or nevirapine
with indinavir or lopinavir/ritonavir, the AUC of
the PIs are reduced by about 33%. To offset
this interaction, providers need to increase
the PI dosage: for indinavir the dosage needs
to be increased to 1000mg every eight hours,
and for lopinavir/ritonavir, the dosage needs
to be increased to four capsules
(533mg/133mg) twice daily.17,18 Conversely,
as delavirdine is a potent inhibitor of CYP3A4,
concurrent use with indinavir requires a
dosage reduction to 600 mg every eight
hours.17 No data exist that describe the
pharmacokinetic interaction between
lopinavir/ritonavir and delavirdine. 
Concurrent use of the two new PIs atazanavir
and fosamprenavir with either efavirenz or
nevirapine also result in reduction in PI levels.
However, instead of dosage adjustments,
data suggest that the addition of ritonavir to
these PIs is a viable option to offset the reduc-
tions in PI drug level. For example, during
concurrent use of atazanavir and efavirenz,
atazanavir AUC was reduced by about 74%.19
To offset the interaction, providers need to
reduce the atazanavir dosage to 300mg once
daily and also add ritonavir 100mg once daily.
When boosted fosamprenavir once daily is
used concurrently with efavirenz, fosampre-
navir should be given 1400mg with 300mg of
ritonavir once daily or fosamprenavir 700mg
with ritonavir 100mg both twice daily.20
Though data evaluating the drug interaction
between nevirapine and either atazanavir or
fosamprenavir are unavailable, expert opinion
suggests that the same dosage adjustments
should be made, given the similarity in
efavirenaz and nevirapine metabolism. Data
combining these medications with delavirdine
is not available. See Table 2 for a summary of
dosage recommendations with select PI and
NNRTI combinations.  
Protease Inhibitors
All PIs are potent inhibitors of CYP3A4, and
as a result, drug interactions are often very
complex. As a result of CYP3A4 inhibition,
medication levels of agents also metabolized
by the same izoenzyme have the potential to
be markedly increased by the PI, potentially
leading to an increased incidence of adverse
effects. PIs have differing affinities for the
CYP3A4 isoenzyme. The most potent
inhibitor of CYP3A4 is ritonavir, whereas the
least potent is saquinavir; CYP3A4 inhibition
associated with indinavir, nelfinavir, and
amprenavir, and atazanavir tends to be inter-
mediate.21 Ritonavir is often the most likely
medication in the PI class to cause drug inter-
actions because in addition to its CYP3A4
inhibition, it also inhibits CYP2D6 and induces
CYP1A2 and CYP2C9. However, ritonavir is
often used to enhance the pharmacokinetic
parameters of co-administered PIs due to its
potent inhibition of their metabolism by
CYP3A4. 
Numerous medications should be avoided
when using PI-based therapy. The benzodi-
azapines midazolam and triazolam are con-
traindicated, as these medications are metab-
olized by CYP3A4 and their concentrations
can be markedly increased, resulting in pro-
longed sedation. Though the benzodiazapine
alprazolam may also be increased by concur-
rent PI therapy, low doses may be acceptable
t  use. Other potential alternatives to these
agents include lorazepam, oxazepam, or
temazepam, as these medications are not
metabolized by CYP450.21
Hyperlipidemia is a common occurrence with
Clinically Significant Drug
Interactions...(continued from page 2)
Continued on page 5
TABLE 2: Dosing Recommendations when Combining Non Nucleoside
Reverse Transcriptase Inhibitors and Protease Inhibitors 
Protease Inhibitor/Non Nucleoside
Reverse Transcriptase Inhibitor
Combination
Indinavir with efavirenz or nevirapine
Indinavir with delavirdine
Amprenavir with efavirenz or nevirap-
ine
Lopinavir/ritonavir with efavirenz or
nevirapine
Atazanavir with efavirenz (and proba-
bly nevirapine, though dosages have
not been established with nevirapine) 
Fosamprenavir with efavirenz (and
probably nevirapine, though dosages
have not been established with nevi-
rapine)
Dosage recommendation
Standard dose for efavirenz and nevirapine.
Increase indinavir dosage to 1000mg every
eight hours.
Standard dose delavirdine. Decrease indi-
navir dosage to 600mg every eight hours.
Standard dose for efavirenz and nevirapine.
Increase amprenavir dosage to 1200mg
three times daily.
Standard dose for efavirenz and nevirapine.
Increase lopinavir/ritonavir dose to
533mg/133mg (four capsules) twice daily. 
Standard dose for efavirenz and probably
nevirapine.Give atazanavir 300mg once
daily AND add ritonavir 100mg once daily
Standard dose for efavirenz and probably
nevirapine. If using fosamprenavir with riton-
avir twice daily, give fosamprenavir 700mg
with ritonavir 100mg twice daily.  If using fos-
amprenavir with ritonavir once daily, give
fosamprenavir 1400mg with ritonavir 300mg
once daily. 
Data from references 17-21.
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5PI therapy, though it may also be associated
with stavudine and efavirenz. As a result,
providers often treat hyperlipidemia with
either fibric acid derivatives or with HMG-CoA
reductase inhibitors, also referred to as
statins. Although drug interactions with the
fibric acid derivatives have not been identi-
fied, the use of certain statins is contraindicat-
ed with the use of a PI. The two most prob-
lematic statins are simvastatin and lovastatin,
as these agents are extensively metabolized
via CYP3A4.22 When used concurrently with
PIs, these statin levels are markedly
increased, placing the patient at risk for
myopathy, rhabdomyolysis, and possibly
renal failure and death. Statins that are con-
sidered safe include pravastatin or fluvastatin,
as they have minimal effect on CYP450,
therefore reducing the risk of drug interac-
tions. Another potential option is atorvastatin,
however CYP3A4 is involved with its metabo-
lism. Use of atorvastatin with PI therapy
should be done only with the lowest available
dosages and with close follow-up for potential
hepatotoxicity and muscle toxicity. The
newest statin, rosuvastatin, cannot be recom-
mended as no drug interaction studies exist
evaluating concurrent PI use.
The use of PIs (and NNRTIs) often compli-
cates the treatment of mycobacterial infec-
tions such as tuberculosis and MAC because
rifampin and rifabutin are potent inducers of
CYP3A4, leading to significant reductions in
PI levels. However, rifampin is much more
problematic, as it is a more potent inducer of
CYP3A4 compared to rifabutin. Therefore,
concurrent use of rifampin with PI regimens
that do not include ritonavir is generally con-
traindicated due to risks of subtherapeutic lev-
els of PIs that can result in either virologic fail-
ure or resistance.  
Herbal therapy is common in the setting of
HIV infection.23 Oftentimes, herbal therapies
have not been studied with concurrent
HAART, and therefore their use should be dis-
couraged unless data evaluating their effect
on HAART are available. St. John's wort and
garlic supplementation significantly reduce
the levels of the PIs indinavir and saquinavir
soft gel capsule, respectively.24,25Since other
PIs and NNRTIs are also metabolized by
CYP3A4, similar interactions with other med-
ications in these classes would be expected.
Therefore, patients should be encouraged to
avoid St. John's wort, garlic supplements, and
other herbal therapies that have not been for-
mally studied with PIs. The herbal therapy
milk thistle, often used as a hepatoprotectant,
has been shown to have minimal effects on
the PI indinavir.26 Providers choosing to offer
milk thistle to patients may be able to do so
safely with PI- and NNRTI-based therapies;
however, data demonstrating its effect on PIs
exist only for indinavir. 
Drugs for erectile dysfunction, such as silde-
nafil, vardenafil and the recently approved
tadalafil, can also have their levels increased
significantly by concurrent PI use.27-29
Specifically, sildenafil levels can be increased
from two to eleven-fold when used concur-
rently with PI therapy. Therefore, clinicians
should prescribe, at most, 25mg every 48
hours initially. For patients who do not
respond to 25mg, consideration for using
higher doses should only be done with
extreme caution. PIs can also increase varde-
nafil concentrations. 
Current guidelines from the product labeling
suggest that for patients on a PI-based regi-
men that does not include ritonavir, the maxi-
mum initial dose of vardenafil should be
2.5mg, without repeating the dose for 24
hours.29 For patients receiving ritonavir even
at low doses, the maximum initial vardenafil
dose should be 2.5mg and should not be
repeated for 72 hours.29 Tadalafil was also
recently approved; maximum doses used
should not exceed 10mg every 72 hours for
patients receiving concurrent PI therapy.30
Possible toxicities from these drugs include
priapism, hypotension, and visual color
changes.  
Clinically Significant Drug
Interactions...(continued from page 4)
Continued on page 6
TABLE 3: Drugs to Avoid With PI-Based HAART Regimens 
Drug
Ergot alkaloids such
as dihydroergota-
mine, ergonovine,
ergotamine, 
methylergonovine
Simvastatin, lovas-
tatin, high dose 
atorvastatin
Phenytoin, 
carbamazepine, 
phenobarbital
Alprazolam, 
midazolam, triazolam
GI motility agents
St. John's wort
Garlic
Pimozide
Rifampin
Amiodarone,
propafenone, bepridil,
quinidine, flecainide
Proton Pump
Inhibitors such as
omeprazole,
esomeprazole, lanso-
prazole, rabeprazole,
pantoprazole
Interaction
Impaired hepatic metabolism
from PI reported to increase
risk of ergotamine toxicity
HMG CoA reductase inhibitor
levels markedly increased
Potential for increased metabo-
lism of PI, leading to virologic
failure
Potential for prolonged or
increased sedation or respira-
tory depression
Cisapride
Significant decrease in PI (IDV
studied) levels, potentially lead-
ing to virologic failure or resis-
tance
Significant decrease in PI
(SQV studied) levels, potential-
ly leading to virologic failure or
resistance
Potential increased risk of car-
diac toxicity with concurrent
ritonavir use
Significant decrease in PI con-
centrations, potentially leading
to virologic failure 
May use with full dose ritonavir
Potential increased risk for
severe cardiac arrhythmias
with concurrent ritonavir use
Significant reductions in
atazanavir plasma concentra-
tions
Recommendation
Avoid concurrent use with
PI therapy. Consider alter-
native drugs such as
sumatriptan.
Select pravastatin or low
dose atorvastatin during
concurrent PI therapy as
alternatives.
Avoid concurrent use if
possible. Consider alterna-
tive anticonvulsant during
PI therapy.
Avoid concurrent use.
Consider zolpidem or
lorazepam.
Contraindicated due to
marked increase in cis-
apride levels and potential
for QT prolongation
Avoid concurrent use dur-
ing PI therapy.
Avoid concurrent use with
PI therapy.
Avoid concurrent use with
ritonavir-based regimens,
including lopinavir/ritonavir.
Consider rifabutin as an
alternative. 
Avoid concurrent use with
ritonavir-based regimens,
including lopinavir/ritonavir.
Avoid concurrent use with
atazanavir; consider use of
an H2 receptor antagonist
separated by at least 12
hours from atazanavir
administration.
Adapted from reference 19, 21
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HIV-infected patients may either have a
seizure disorder or may require seizure pro-
phylaxis due to OIs that involve the central
nervous system. This often becomes prob-
lematic in the setting of HAART due to very
limited data on concurrent use of anticonvul-
sants and PIs. Use of the anticonvulsants
phenytoin, phenobarbital, and carba-
mazepine is of particular concern as they
induce CYP450 enzymes that may lead to
reduced PI or NNRTI levels.21 In fact, one
case report in the literature describes ART
failure possibly related to carbamazepine
therapy in a patient receiving a PI.31 In this
case, 200 mg of carbamazepine was taken
with 800 mg of indinavir every eight hours,
which led to subsequent virologic failure.
Therefore, concurrent use of these drugs with
PIs should be avoided, and a different anti-
convulsant should be considered. More
recently, a drug interaction study was report-
ed between lopinavir/ritonavir and pheny-
toin.32 When used together, a dual interaction
occurred, such that the levels of both lopinavir
and phenytoin were markedly reduced.
Therefore, providers should avoid this combi-
nation and select an alternative HAART regi-
men or an alternative anticonvulsant. One
potential option is the use of levetiracetam, an
anticonvulsant that has minimal drug interac-
tions. Use of this medication in HIV-infected
patients has not been studied, and therefore
its use for treatment or prevention of seizures
should only be done with close consultation
with a neurologist. Whenever possible,
patients who require concurrent HAART and
anticonvulsant therapy should undergo peri-
odic monitoring of anticonvulsant drug levels.
For some PIs, therapeutic drug monitoring
may also be an option to ensure that ade-
quate levels are being attained. Consensus
trough concentrations have been established
and are available in the most recent revision
of the federal Department of Health and
Human Services Guidelines.1
Patients infected with HIV-1 may require anti-
fungal therapy for such infections as crypto-
coccal meningitis, or candidiasis. With regard
to PI drug interactions, the safest of the oral
medications is fluconazole, as drug interac-
tions are minimal.33,34 However, the azole
antifungal ketoconazole is a potent CYP3A4
inhibitor and increases the level of drug expo-
sure to saquinavir and amprenavir by 190%
and 31%, respectively.35,36 Conversely, riton-
avir and lopinavir/ritonavir have demonstrated
a three-fold increase in ketoconazole levels
when used concurrently. Therefore doses
>200 mg/day of ketoconazole are not recom-
mended when using these medications con-
currently.18 In general, ketoconazole should
be avoided with concurrent HAART. The
newest azole antifungal, voriconazole, has
significant activity against aspergillosis and
candida albicans. Its use for treatment of can-
didiasis in HIV-infected patients has been
established; however, drug interaction data
only exist for concurrent use of indinavir,
where no clinically significant interaction
occurred.37 Although extrapolation to other
PIs may be possible, until data are available,
use of this azole with other PI-containing reg-
imens (especially those that contain ritonavir)
should be undertaken when an alternative
azole cannot be used, and with close moni-
toring for voriconazole toxicity, such as ele-
vated transaminases and visual toxicity.   
One of the recently approved PIs for use in
the U.S. is atazanavir.19 Drug interactions with
atazanavir are very similar to the other PIs;
however, some differences do exist. In partic-
ular, atazanavir is a pH-dependent medica-
tion, requiring an acidic environment for
absorption. As a result, the use of drugs that
may alter the gastric pH are likely to be prob-
lematic. Since antacids may reduce
atazanavir absorption, atazanavir should be
administered two hours before or one hour
after antacids. Proton pump inhibitors (PPIs)
such as lansoprazole and omeprazole signifi-
cantly alter the gastric pH for prolonged peri-
ods of time (often lasting longer than 24
hours), the atazanavir product labeling rec-
ommends that PPIs should not be used con-
currently with atazanavir. As an alternative,
providers may consider the use of a once
daily histamine-2 (H-2) receptor antagonist
separated by 12 hours from atazanavir. The
current thought is that H2 blockers provide
less prolonged suppression of acid, and, if
separated, the interaction should be mini-
mized. However, no data exist to prove or
refute this theory.19
Other significant drug interactions may also
occur with concurrent PI use. Table 3 summa-
rizes medications that should generally be
voided with concurrent PI therapy. 
Conclusions
Drug interactions are often complex and may
be difficult to predict due to limited studies.
Providers should be diligent in educating
themselves about routes of metabolism for
HAART and commonly prescribed medica-
tions to help recognize potential medications
that may be problematic. As therapy for HIV
changes very rapidly, providers may utilize
internet resources to help screen for potential
drug interactions and to identify new treat-
ment options and issues surrounding HIV
i fection (See Resources on p.8). With such
interventions, toxicity or adverse events
a sociated with drug interactions may be
prevented.
Clinically Significant Drug
Interactions...(continued from page 5)
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7Drug Interactions with HAART and Methadone
DRUG
Abacavir
Didanosine, buffered tablet
Didanosine, enteric-
coated capsule
Lamivudine
Stavudine
Tenofovir disoproxil fumarate
Zalcitabine
Zidovudine
Delavirdine
Efavirenz
Nevirapine
Amprenavir
Indinavir
Lopinavir-ritonavir
Nelfinavir
Ritonavir
Saquinavir, hard-gel capsule
Saquinavir, soft-gel capsule
EFFECT OF ANTIRETROVIRAL 
THERAPY ON METHADONE
Decreased methadone clearance 25%
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown
Unknown, although potential increased
methadone effect
Decreased methadone levels 57%
Decreased methadone levels 51%
Decreased methadone AUC 35%
No significant change in methadone AUC
Decreased methadone AUC 36%
Decreased methadone AUC 40%
Decreased methadone AUC 36%
Unknown with saquinavir as sole PI
Unknown with saquinavir as sole PI;
unbound methadone concentrations
unchanged when using saquinavir and
ritonavir concurrently
EFFECT OF METHADONE ON 
ANTIRETROVIRAL THERAPY
Decreased abacavir peak concentration 34%
Decreased didanosine AUC 57%
No significant change in didanosine AUC
No significant change when given as 
zidovudine-lamivudine
Decreased stavudine AUC 23%
No significant change in tenofovir DF
Unknown
Increased zidovudine AUC 41%
No change in delavirdine or N-delavirdine
Unknown
Unknown 
Decreased amprenavir AUC, Cmax, Cmin
Insignificant change in indinavir AUC;
increased indinavir Cmin 50%-100%;
decreased indinavir Cmax 16%-36%
Unknown
Decreased nelfinavir metabolite (M8) AUC
53%; clinical significance unknown
Unknown
Unknown with saquinavir as sole PI
Unknown with saquinavir as sole PI; potential
reduction in saquinavir Cmin when using
saquinavir and ritonavir concurrently
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Clinically Significant Drug Interactions...
(continued from page 6)
NUCLEOSIDE/NUCLEOTIDE ANALOGUES
NON NUCLEOSIDE ANALOGUES
PROTEASE INHIBITORS (PIS)
AUC, area under the concentration time curve; Cmax, maximum drug concentration or peak level; Cmin, minimum drug concentration or trough level.
Drug Interactions Associated With HAART: Focus on Treatments for Addiction and Recreational Drugs. AIDS Reader 13(9):433-450, 2003. Available at
www.medscape.com/viewarticle/461892_4
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Using Enfuvirtide (T20)
in Clinical Care 
January 15, 2004
Boston, Massachusetts
Seminar topics will include:
Antiretroviral Drugs; Drug
Resistance; HIV/AIDS 
Treatment or Therapies
Sponsored by The New England
AIDS Education and Training
Center (NEAETC). 
Call: 617.262-5657 
Visit: www.neaetc.org
The 11th Conference 
on Retroviruses and 
Opportunistic Infection
February 8-11, 2004
San Francisco, California
Contact: Office of the Retrovirus
Conference Secretariat
Call: 703.535.6862
Fax: 703.535.6899
Email: info@retroconference.org
Visit: www.retroconference.org
8th North American Region
Conference of the International
Union Against Tuberculosis 
and Lung Disease 
February 26-28, 2003
Austin, Texas
Themes will include Global
Threats to Regional TB; 
Cross-Border TB Issues;
Treatment Strategies and
Disparities of TB Control in Low-
Incident Countries; and 
Scientific Challenges for 
TB Control: Resistance, 
Drug Discovery, and 
Laboratory Methods. 
Call: 312.243.2000; Fax:
312.243.3954; TB@alamc.org; 
www.lungchicago.org or
www.iuatld.org. 
Management of HIV/AIDS in 
the Correctional Setting:
A Live Satellite 
Videoconference Series
Albany Medical Center
March 16, 2004
12:30 PM - 3:30 PM EST
CME and Nursing credits available
Call: 518.262.4674
Email: ybarraj@mail.amc.edu 
To register as a site in your area
visit www.amc.edu/Patient/hiv/
hivconf/index.htm.
Save the 
Dates
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Rise in Syphilis Among MSM in San
Francisco Linked to Internet
The internet is a major factor in San Francisco's
increase in early syphilis infections among men
who have sex with men (MSM), according to a
recent study from the CDC. A focus on data for
415 MSM diagnosed with early syphilis in 2002
found that internet chat rooms were the most
common venues for meeting partners. Last year,
the city reported the highest rates of first and sec-
ond-stage syphilis of any metropolitan area in the
nation. Between 1998-2002, early syphilis cases
increased from 41 to 495. Officials noted at the
time the proportion of cases among MSM had
jumped from 22 percent in 1998 to 88 percent in
2002. However, the CDC and San Francisco
Department of Public Health officials say that
they have evidence that internet-based partner
notification can be an effective tool for finding and
treating early syphilis infections.
"Internet Use and Early Syphilis Infection Among
Men Who Have Sex with Men - San Francisco,
California, 1999-2003," MMWR
(2003;52(50):1229-1232).
Bioequivalence study: 500 mg pill of Invirase
Two 200 mg formulations of Saquinavir (SQV)
are currently marketed for oral administration in
the treatment of HIV infection: Invirase, a hard
gelatin capsule (saquinavir mesylate) and
Fortovase, a soft gelatin capsule (saquinavir
base). Both formulations have shown good effi-
cacy and safety when boosted with ritonavir (r) in
a SQV/r dosing of 1000/100 mg bid. The pill
count for a SQV/r regimen using the current 200
mg formulation is 12 pills per day. Roche is devel-
oping a 500 mg saquinavir mesylate tablet that is
smaller than the existing 200 mg formulation,
allowing the use of only two SQV tablets twice
daily in combination with ritonavir. The lower pill
count and improved convenience may improve
adherence to SQV/r regimens.
Boffito, Marta et al 9th EACS, October 2003,
Warsaw, Poland. Oral Abstract
Study: Safety, Tolerability, and Efficacy of
Interferon/Ribavirin Combination Therapy in
Methadone Maintenance (MM) Patients with
Active Hepatitis C (HCV)
In this study from the University of California, 78
percent of MM treated patients completed the six
to 12 month course of interferon/ribavirin combi-
nation therapy. The end-of-treatment virologic
response rate was 64% in patients completing
treatment and 54% in an intent-to-treat analysis.
Despite the fact that MM patients exhibit a num-
b r of factors that make HCV treatment challeng-
ing, such as older age, a higher prevalence of
psychiatric illness, and more advanced liver dis-
ease, their end-of-treatment response rate to
therapy is similar to that of patients without a his-
to y of IDU. These preliminary suggest that that
MM patients should be considered as potential
candidates for HCV treatment. 
Sylvestre, DL. Treating Hepatitis C in
Methadone Maintenance Patients: An Interim
Analysis, Drug and Alcohol Dependence 67 (2)
(2002) pp. 117 - 123.
Study: Gilead Announces Preliminary
Results from 48-Week Phase III Study of
Emtricitabine in Patients with Chronic
Hepatitis B 
Preliminary results from a Phase III clinical trial
comparing the efficacy and safety of emtricitabine
200 mg once daily versus placebo in patients with
chronic hepatitis B have been released. The
results demonstrate improvements in liver histol-
ogy in 62% of patients who received the drug
compared to 25% of patients who received place-
bo (p less than 0.001). Improvement in liver his-
tology was the primary endpoint in this study.
Gilead expects to present these data in detail at
a scientific conference next year.
www.natap.org 11/26/03
New CDC HIV Prevention Funding
Emphasizes Effectiveness, Focuses on
Those Already Infected
The federal Centers for Disease Control and
Prevention (CDC) has announced $49 million in
HIV prevention grants that require grantees to
prove that their efforts are effective and focus
more on doing prevention among people who are
already infected with the virus. "The announce-
ment included some specific items that are called
program performance indicators," said Dr. Harold
W. Jaffe, director of CDC's National Center for
HIV, STD and TB Prevention. "They attempt to
set goals." The CDC expects to fund roughly 160
grants ranging in amounts from $100,000 to
$500,000, according to the December 3, 2003
announcement. The grants will run for five years,
but the $49 million represents only the first year's
funding.
HIV Update, 12/15/03
Inside News
Resources
www.hiv.medscape.com
New data from conferences, CE articles on HIV
related topics and more.
www.aidsinfo.nih.gov
DHHS Guidelines for treatment of HIV infected
adults, adolescents, children...
www.hivandhepatitis.com
Treatment/developments for Hepatits A, B and C
and conferences/new journal articles related to
HIV/AIDS. 
www.hopkins-aids.edu
HIV clinical trials/developments and animation of
viral life cycle that includes action of ART 
www.hivguidelines.org
NYSDOH AIDS Institute Clinical Guidelines for
adults, pediatrics, ART in adults, and more.
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Self-Assessment Test for Continuing Medical Education Credit
Brown Medical School designates this educational activity for 1 hour in category 1 credit toward the AMA Physician’s Recognition Award.
To be eligible for CME credit, answer the questions below by circling the letter next to the correct answer to each of the questions. 
A minimum of 70% of the questions must be answered correctly. This activity is eligible for CME credit through July 31, 2004. 
The estimated time for completion of this activity is one hour and there is no fee for participation.
1. The following two antiretroviral agents compete for the same
phosphorylation site in the growing chain of HIV DNA, resulting in
an antagonistic, pharmacodynamic interaction:
(a) zidovudine and stavudine 
(b) zidovudine and didanosine
(c) didanosine and  stavudine
(d) lamivudine and emtricitabine
2. The following antiretroviral agent contains magnesium and calci-
um and therefore interferes with the absorption of antibiotics such
as ciprofloxacin, tetracycline and doxycycline.
(a) zidovudine
(b) didanosine 
(c) abacavir
(d) tenofovir
3. Which of the following statements is true:
(a)  Nevirapine and efavirenz are, in general, inhibitors of 
CYP3A4, while delavirdine is an inducer of CYP3A4
(b)  when nevirapine is given concurrently with methadone, 
intoxication symptoms may occur as a result of increased 
methadone levels
(c)  When enteric-coated ddI is co-administered with tenofovir, 
the ddI AUC increases 60%.
(d)  Abacavir increases the metabolism of oral contraceptives 
and can lead to contraceptive failure; therefore providers 
should recommend alternate methods of birth control for 
patients receiving abacavir.
4. When used together with one of the following antiretrovirals, the
AUC and Cmax of clarithromycin decreased 39% and 26%,
respectively. Concurrent use of clarithromycin should therefore be
avoided in patients receiving:  
(a) nelfinavir
(b) efavirenz
(c) lopinavir
(d) abacavir
5. The concentrations of some "statins" are markedly increased by
concurrent protease inhibitor therapy, placing the patient at risk for
myopathy, rhabdomyolysis, and possibly renal failure and death.
Statins which are considered safe because of minimal cytochrome
P450 interactions include:
(a)  lovastatin and atorvastatin
(b)  simvastatin and lovastatin
(c)  pravastatin and fluvastatin
(d)  lovastatin and pravastatin
6. When rifampin must be used for treatment of a mycobacterial
infection, the following is an appropriate concurrent dose:
(a) Nelfinavir 1250 mg p.o. bid
(b) Indinavir 800 mg p.o. tid
(c) Saquinivir 1200 mg p.o. bid
(d) Efavirenz 800 mg p.o. qd
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HEPP Report Evaluation
5 Excellent    4 Very Good    3 Fair    2 Poor    1 Very Poor
1. Please evaluate the following sections with respect to:
educational value clarity
Main Article 5  4  3  2  1   5  4  3  2  1      
Inside News 5  4  3  2  1   5  4  3  2  1
Save the 
Dates 5  4  3  2  1   5  4  3  2  1
2. Do you feel that HEPP Report helps you in your work?
Why or why not?
3. What future topics should HEPP Report address?
4. How can HEPPReport be made more useful to you?
5. Do you have specific comments on this issue?
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